Melanie Ufkin

795 total citations
13 papers, 476 citations indexed

About

Melanie Ufkin is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Melanie Ufkin has authored 13 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 4 papers in Genetics. Recurrent topics in Melanie Ufkin's work include Lymphoma Diagnosis and Treatment (7 papers), CAR-T cell therapy research (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Melanie Ufkin is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), CAR-T cell therapy research (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Melanie Ufkin collaborates with scholars based in United States, Poland and Spain. Melanie Ufkin's co-authors include Pradeep Sathyanarayana, Sarah Peterson, Clare Bates Congdon, Jeffrey Thompson, Lucy Liaw, Christine W. Duarte, Xuehui Yang, Heather Driscoll, Hesham Mohamed and Sung Yong Oh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The FASEB Journal.

In The Last Decade

Melanie Ufkin

12 papers receiving 469 citations

Peers

Melanie Ufkin
Divya Iyer United States
Jessica Alluin United States
Marcus R. Breese United States
Fei‐Xiang Ding China
Voahangy Randrianarison France
Mariana Boroni Brazil
Daneen Schaeffer United States
Nge Cheong Singapore
Yogesh Srivastava China
Divya Iyer United States
Melanie Ufkin
Citations per year, relative to Melanie Ufkin Melanie Ufkin (= 1×) peers Divya Iyer

Countries citing papers authored by Melanie Ufkin

Since Specialization
Citations

This map shows the geographic impact of Melanie Ufkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Ufkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Ufkin more than expected).

Fields of papers citing papers by Melanie Ufkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Ufkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Ufkin. The network helps show where Melanie Ufkin may publish in the future.

Co-authorship network of co-authors of Melanie Ufkin

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Ufkin. A scholar is included among the top collaborators of Melanie Ufkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Ufkin. Melanie Ufkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Gray, Carl, Silvana Novelli, Tuba Hacıbekiroğlu, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).. Journal of Clinical Oncology. 42(16_suppl). TPS7099–TPS7099. 4 indexed citations
2.
Cho, Seok‐Goo, Tae‐Min Kim, Aditi Choudhry, et al.. (2024). Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study. Blood. 144(Supplement 1). 6302–6302. 2 indexed citations
3.
4.
Poon, Michelle, Jan Walewski, Isidro Jarque, et al.. (2023). ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2. Hematological Oncology. 41(S2). 141–142. 5 indexed citations
5.
Walewski, Jan, Tae Min Kim, Seok‐Goo Cho, et al.. (2023). P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2. HemaSphere. 7(S3). e50570ac–e50570ac. 3 indexed citations
6.
7.
Kim, Won-Seog, Tae Min Kim, Seok‐Goo Cho, et al.. (2022). Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2. Blood. 140(Supplement 1). 1070–1071. 24 indexed citations
8.
Zhu, Min, Jurriaan Brouwer‐Visser, Srikanth Ambati, et al.. (2022). Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome. Blood. 140(Supplement 1). 11560–11561. 1 indexed citations
9.
Bannerji, Rajat, Jennifer R. Brown, Ranjana H. Advani, et al.. (2016). Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. Blood. 128(22). 621–621. 15 indexed citations
10.
Ufkin, Melanie, Sarah Peterson, Xuehui Yang, et al.. (2014). miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leukemia Research. 38(3). 402–410. 70 indexed citations
11.
Peterson, Sarah, Jeffrey Thompson, Melanie Ufkin, et al.. (2014). Common features of microRNA target prediction tools. Frontiers in Genetics. 5. 23–23. 339 indexed citations
12.
Sathyanarayana, Pradeep, Arvind Dev, Anamika Pradeep, et al.. (2012). Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2. Blood. 119(23). 5522–5531. 11 indexed citations
13.
Ufkin, Melanie & David J. Hall. (2006). Immunological Impact on Macrophages Exposed to Nanoparticles. The FASEB Journal. 20(5). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Divya Iyer Breakdown of academic impact, for papers by Jessica Alluin Breakdown of academic impact, for papers by Marcus R. Breese Breakdown of academic impact, for papers by Fei‐Xiang Ding Breakdown of academic impact, for papers by Voahangy Randrianarison Breakdown of academic impact, for papers by Mariana Boroni Breakdown of academic impact, for papers by Daneen Schaeffer Breakdown of academic impact, for papers by Nge Cheong Breakdown of academic impact, for papers by Yogesh Srivastava
Rankless by CCL
2026